Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology
- PMID: 15541309
- DOI: 10.1016/j.neuron.2004.11.005
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology
Abstract
We have previously linked families with autosomal-dominant, late-onset parkinsonism to chromosome 12p11.2-q13.1 (PARK8). By high-resolution recombination mapping and candidate gene sequencing in 46 families, we have found six disease-segregating mutations (five missense and one putative splice site mutation) in a gene encoding a large, multifunctional protein, LRRK2 (leucine-rich repeat kinase 2). It belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains. Within affected carriers of families A and D, six post mortem diagnoses reveal brainstem dopaminergic degeneration accompanied by strikingly diverse pathologies. These include abnormalities consistent with Lewy body Parkinson's disease, diffuse Lewy body disease, nigral degeneration without distinctive histopathology, and progressive supranuclear palsy-like pathology. Clinical diagnoses of Parkinsonism with dementia or amyotrophy or both, with their associated pathologies, are also noted. Hence, LRRK2 may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism.
Comment in
-
Protein kinases linked to the pathogenesis of Parkinson's disease.Neuron. 2004 Nov 18;44(4):575-7. doi: 10.1016/j.neuron.2004.11.008. Neuron. 2004. PMID: 15541303
Similar articles
-
Molecular genetic findings in LRRK2 American, Canadian and German families.J Neural Transm Suppl. 2006;(70):231-4. doi: 10.1007/978-3-211-45295-0_35. J Neural Transm Suppl. 2006. PMID: 17017534 Review.
-
Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.Brain Res. 2007 Jun 25;1155:208-19. doi: 10.1016/j.brainres.2007.04.034. Epub 2007 Apr 19. Brain Res. 2007. PMID: 17512502
-
PINK1-linked parkinsonism is associated with Lewy body pathology.Brain. 2010 Apr;133(Pt 4):1128-42. doi: 10.1093/brain/awq051. Epub 2010 Mar 30. Brain. 2010. PMID: 20356854
-
Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.J Neurol Sci. 2008 Jul 15;270(1-2):94-8. doi: 10.1016/j.jns.2008.02.010. Epub 2008 Mar 19. J Neurol Sci. 2008. PMID: 18353371
-
Deciphering the role of heterozygous mutations in genes associated with parkinsonism.Lancet Neurol. 2007 Jul;6(7):652-62. doi: 10.1016/S1474-4422(07)70174-6. Lancet Neurol. 2007. PMID: 17582365 Review.
Cited by
-
Mitochondrial quality control: from molecule to organelle.Cell Mol Life Sci. 2021 Apr;78(8):3853-3866. doi: 10.1007/s00018-021-03775-0. Epub 2021 Mar 29. Cell Mol Life Sci. 2021. PMID: 33782711 Free PMC article. Review.
-
Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo.Mol Neurodegener. 2021 May 24;16(1):33. doi: 10.1186/s13024-021-00454-3. Mol Neurodegener. 2021. PMID: 34030727 Free PMC article.
-
Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers.PLoS One. 2012;7(12):e52312. doi: 10.1371/journal.pone.0052312. Epub 2012 Dec 27. PLoS One. 2012. PMID: 23300640 Free PMC article.
-
LRRK2 and the Endolysosomal System in Parkinson's Disease.J Parkinsons Dis. 2020;10(4):1271-1291. doi: 10.3233/JPD-202138. J Parkinsons Dis. 2020. PMID: 33044192 Free PMC article. Review.
-
Transgenic LRRK2 (R1441G) rats-a model for Parkinson disease?PeerJ. 2015 May 12;3:e945. doi: 10.7717/peerj.945. eCollection 2015. PeerJ. 2015. PMID: 26020005 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases